CA2958033C - Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia - Google Patents

Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia Download PDF

Info

Publication number
CA2958033C
CA2958033C CA2958033A CA2958033A CA2958033C CA 2958033 C CA2958033 C CA 2958033C CA 2958033 A CA2958033 A CA 2958033A CA 2958033 A CA2958033 A CA 2958033A CA 2958033 C CA2958033 C CA 2958033C
Authority
CA
Canada
Prior art keywords
patients
composition
stroke
amino acids
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2958033A
Other languages
English (en)
French (fr)
Other versions
CA2958033A1 (en
Inventor
Paolo Luca Maria Giorgetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Professional Dietetics SpA
Original Assignee
Professional Dietetics SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Professional Dietetics SpA filed Critical Professional Dietetics SpA
Publication of CA2958033A1 publication Critical patent/CA2958033A1/en
Application granted granted Critical
Publication of CA2958033C publication Critical patent/CA2958033C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2958033A 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia Active CA2958033C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO20140806 2014-10-08
ITTO2014A000806 2014-10-08
PCT/IB2015/057662 WO2016055948A1 (en) 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Publications (2)

Publication Number Publication Date
CA2958033A1 CA2958033A1 (en) 2016-04-14
CA2958033C true CA2958033C (en) 2019-07-16

Family

ID=52101507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2958033A Active CA2958033C (en) 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Country Status (14)

Country Link
US (1) US9707198B2 (enExample)
EP (1) EP3006027B1 (enExample)
JP (1) JP6447716B2 (enExample)
KR (1) KR102077374B1 (enExample)
AU (1) AU2015329581B2 (enExample)
CA (1) CA2958033C (enExample)
DK (1) DK3006027T3 (enExample)
ES (1) ES2651903T3 (enExample)
HU (1) HUE035699T2 (enExample)
NO (1) NO3006027T3 (enExample)
NZ (1) NZ728962A (enExample)
PL (1) PL3006027T3 (enExample)
RU (1) RU2668373C1 (enExample)
WO (1) WO2016055948A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294279T3 (pl) * 2015-05-14 2020-06-29 Professional Dietetics International S.R.L. Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii
IT201700087376A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
IT1320783B1 (it) * 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US20030060421A1 (en) * 2001-07-19 2003-03-27 Neuron Therapeutics, Inc. Kits and compositions supporting intracranial perfusions
EP2275084A1 (en) * 2009-07-15 2011-01-19 Unilever PLC Oral care composition
RU2012105901A (ru) * 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
PH12013501571A1 (en) * 2011-03-01 2013-09-30 Nestec Sa Extensional viscosity to promote safe swallowing of food boluses
WO2012133198A1 (ja) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
WO2012142678A1 (en) * 2011-04-21 2012-10-26 Fit-Bioceuticals Limited Weight loss composition
RU2526826C2 (ru) * 2012-10-24 2014-08-27 Николай Владимирович Соловьёв Композиция для парентерального введения, способ получения и применение композиции

Also Published As

Publication number Publication date
WO2016055948A1 (en) 2016-04-14
AU2015329581B2 (en) 2019-02-07
AU2015329581A1 (en) 2017-03-02
RU2668373C1 (ru) 2018-09-28
ES2651903T3 (es) 2018-01-30
KR102077374B1 (ko) 2020-02-13
CA2958033A1 (en) 2016-04-14
KR20170057308A (ko) 2017-05-24
NO3006027T3 (enExample) 2018-04-14
JP2017530103A (ja) 2017-10-12
JP6447716B2 (ja) 2019-01-09
NZ728962A (en) 2019-05-31
EP3006027A1 (en) 2016-04-13
US9707198B2 (en) 2017-07-18
US20160101078A1 (en) 2016-04-14
EP3006027B1 (en) 2017-11-15
DK3006027T3 (en) 2017-12-18
PL3006027T3 (pl) 2018-02-28
HUE035699T2 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
JP5550002B2 (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
CA2703693C (en) Anti-fatigue agent comprising amino acid composition
EP2512236A1 (en) Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
Aquilani et al. Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
US5276018A (en) Composition comprising amino acids and methods for decreasing muscle breakdown
KR20090100385A (ko) 신규조성물 및 그 용도
Fouque Nutritional requirements in maintenance hemodialysis
US9707198B2 (en) Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia
CN100448453C (zh) 治疗或预防慢性创伤的方法及其中所使用的包含甘氨酸和/或亮氨酸的全营养组合物
JP2016210720A (ja) 運動機能改善剤、呼吸機能改善剤または認知能改善剤
CN108371326B (zh) 一种降血糖的功能性组合物
CN112839528A (zh) 用于促进肌肉生长和功能的组合物及其使用方法
RU2201179C2 (ru) Способ лечения диабетических ретинопатий
Bozzetti et al. Metabolic effects of intraportal nutrition in humans
Kawano et al. Successful treatment of heart failure in an adult patient with Prader-Willi syndrome
JP2023530485A (ja) 運動なしで、筋量、筋力および筋機能を改善するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用法
RU2113227C1 (ru) Способ лечения ожирения
US20210346334A1 (en) Nutritional chromium compositions and methods of use
HK40052650A (en) Compositions and methods of use thereof to promote muscle growth and function

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171026

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251118

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260519

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260720